NOVOZYMES -B- (NZM2 BE) stock market data APIs
€54.2863
0(0%)
as of September 12, 2025
Try our APIs with
free plan!
NOVOZYMES -B- Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for NZM2.BE.
Prev. Close
54.2863
Open
54.2863
High
54.4697
Low
53.7373
52 wk Range
49.3736-65.3076
Market Cap
19 321 M
Dividends (Yield)
0.11
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NOVOZYMES -B- data using free add-ons & libraries
Get NOVOZYMES -B- Fundamental Data
NOVOZYMES -B- Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-21
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NOVOZYMES -B- News
New
Novozymes (CPSE:NSIS B): Taking Stock of Valuation as Market Sentiment Shifts
Novozymes (CPSE:NSIS B) might not be grabbing headlines with earth-shaking news right now, but that doesn’t mean investors should overlook what’s happening under the surface. Even modest moves can...
Could Gut Microbiome Research Shift Novozymes' Innovation Narrative in Health and Nutrition (CPSE:NSIS B)?
Novonesis and Novo Nordisk have announced a research partnership to explore how the gut microbiome influences metabolic health, aiming to develop synbiotic food supplements and identify novel health b...
Novonesis and Novo Nordisk will explore new solutions to improve metabolic health
Novonesis (Novozymes A/S) Novonesis and Novo Nordisk join forces in a new research collaboration to explore solutions that seek to preserve and optimize metabolic health and well-being for people. C...
Corbion proposes to appoint Per Falholt to the Supervisory Board
Corbion Corbion’s Supervisory Board announces it has nominated Per Falholt for appointment to the Supervisory Board for a term of four years as of the Annual General Meeting of Shareholders (AGM) i...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
